Gabelli Funds LLC trimmed its stake in Grifols SA, Barcelona (NASDAQ:GRFS) by 69.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,333 shares of the biotechnology company’s stock after selling 128,203 shares during the quarter. Gabelli Funds LLC’s holdings in Grifols SA, Barcelona were worth $1,291,000 as of its most recent SEC filing.
A number of other large investors also recently bought and sold shares of GRFS. Lenox Wealth Management Inc. raised its position in Grifols SA, Barcelona by 8,372.9% in the third quarter. Lenox Wealth Management Inc. now owns 5,931 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 5,861 shares during the period. First Republic Investment Management Inc. purchased a new position in shares of Grifols SA, Barcelona in the third quarter worth about $203,000. Dean Capital Investments Management LLC purchased a new position in shares of Grifols SA, Barcelona in the fourth quarter worth about $214,000. Advisory Services Network LLC increased its stake in shares of Grifols SA, Barcelona by 26.2% in the second quarter. Advisory Services Network LLC now owns 9,564 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 1,987 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Grifols SA, Barcelona in the second quarter worth about $223,000. Institutional investors and hedge funds own 22.72% of the company’s stock.
Shares of Grifols SA, Barcelona (NASDAQ GRFS) traded down $0.14 during mid-day trading on Thursday, reaching $22.72. 479,200 shares of the company traded hands, compared to its average volume of 472,409. The company has a quick ratio of 1.39, a current ratio of 3.17 and a debt-to-equity ratio of 1.69. The stock has a market cap of $15,609.33, a P/E ratio of 21.17, a price-to-earnings-growth ratio of 1.53 and a beta of 1.10. Grifols SA, Barcelona has a one year low of $17.24 and a one year high of $25.18.
TRADEMARK VIOLATION NOTICE: “Grifols SA, Barcelona (NASDAQ:GRFS) Holdings Reduced by Gabelli Funds LLC” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://stocknewstimes.com/2018/02/22/gabelli-funds-llc-has-1-29-million-stake-in-grifols-sa-barcelona-grfs.html.
About Grifols SA, Barcelona
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.
Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.